Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

<p>SGLT2 Inhibitors: A Novel Player in the Treatment and Prevention of Diabetic Cardiomyopathy</p>
Na Li, Hong Zhou
Drug Design Development and Therapy (2020) Vol. Volume 14, pp. 4775-4788
Open Access | Times Cited: 46

Showing 1-25 of 46 citing articles:

Ferroptosis and ferritinophagy in diabetes complications
Jiahui He, Zhangwang Li, Panpan Xia, et al.
Molecular Metabolism (2022) Vol. 60, pp. 101470-101470
Open Access | Times Cited: 105
Iron homeostasis and ferroptosis in human diseases: mechanisms and therapeutic prospects
Qin Ru, Yusheng Li, Lin Chen, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 50
Fibrosis of the diabetic heart: Clinical significance, molecular mechanisms, and therapeutic opportunities
Izabela Tuleta, Nikolaos G. Frangogiannis
Advanced Drug Delivery Reviews (2021) Vol. 176, pp. 113904-113904
Open Access | Times Cited: 87
Direct cardio-protection of Dapagliflozin against obesity-related cardiomyopathy via NHE1/MAPK signaling
Ke Lin, Na Yang, Wu Luo, et al.
Acta Pharmacologica Sinica (2022) Vol. 43, Iss. 10, pp. 2624-2635
Open Access | Times Cited: 48
SGLT1: A Potential Drug Target for Cardiovascular Disease
Mengnan Zhao, Na Li, Hong Zhou
Drug Design Development and Therapy (2023) Vol. Volume 17, pp. 2011-2023
Open Access | Times Cited: 36
Common mechanisms underlying diabetic vascular complications: focus on the interaction of metabolic disorders, immuno-inflammation, and endothelial dysfunction
Chongxiang Xue, Keyu Chen, Zezheng Gao, et al.
Cell Communication and Signaling (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 34
Diabetic Cardiomyopathy—From Basics through Diagnosis to Treatment
Ewa Radzioch, Bartłomiej Dąbek, Marta Balcerczyk-Lis, et al.
Biomedicines (2024) Vol. 12, Iss. 4, pp. 765-765
Open Access | Times Cited: 8
Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Regulation of Inflammatory Processes in Animal Models
Sandra Feijóo‐Bandín, Alana Aragón‐Herrera, Manuel Otero-Santiago, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 10, pp. 5634-5634
Open Access | Times Cited: 34
Effects of Liraglutide, Empagliflozin and Their Combination on Left Atrial Strain and Arterial Function
Κ Katogiannis, J Thymis, Foteini Kousathana, et al.
Medicina (2024) Vol. 60, Iss. 3, pp. 395-395
Open Access | Times Cited: 7
Impact of gliflozins on cardiac remodeling in patients with type 2 diabetes mellitus & reduced ejection fraction heart failure: A pilot prospective study. GLISCAR study
Giuseppe Palmiero, Arturo Cesaro, Raffaele Galiero, et al.
Diabetes Research and Clinical Practice (2023) Vol. 200, pp. 110686-110686
Closed Access | Times Cited: 14
Benefits of SGLT2 inhibitors in arrhythmias
Jinghan Gao, Genlong Xue, Ge Zhan, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 20
Clinical Perspectives for Diagnosis and Treatment of Diabetic Cardiomyopathy
David Chen, Andrew Sindone, Michael Huang, et al.
(2025)
Closed Access
Empagliflozin in diabetic cardiomyopathy: elucidating mechanisms, therapeutic potentials, and future directions
Aiswarya Jaiswal, Poonam Yadav, Pushkar Singh Rawat, et al.
Molecular Biology Reports (2025) Vol. 52, Iss. 1
Closed Access
Association of anti-diabetic drugs and COVID-19 outcomes in patients with diabetes mellitus type 2 and cardiomyopathy
Jelena Dimnjaković, Tamara Buble, Pero Ivanko, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 3
Atrial fibrillation in cancer, anticancer therapies, and underlying mechanisms
Adnan Shaaban, Shane S. Scott, Ashley Greenlee, et al.
Journal of Molecular and Cellular Cardiology (2024) Vol. 194, pp. 118-132
Open Access | Times Cited: 3
Unlocking the Potential: Angiotensin Receptor Neprilysin and Sodium Glucose Co-Transporter 2 Inhibitors for Right Ventricle Dysfunction in Heart Failure
Bibhuti B. Das
Medicina (2024) Vol. 60, Iss. 7, pp. 1112-1112
Open Access | Times Cited: 3
Diabetes cardiomyopathy: targeted regulation of mitochondrial dysfunction and therapeutic potential of plant secondary metabolites
Xianglong Pan, Erwei Hao, Fan Zhang, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 3
Sodium glucose co-transporter-2 inhibitor, Empagliflozin, is associated with significant reduction in weight, body mass index, fasting glucose, and A1c levels in Type 2 diabetic patients with established coronary heart disease: the SUPER GATE study
Satılmış Bilgin, Özge Kurtkulağı, Tuba Taslamacıoğlu Duman, et al.
Irish Journal of Medical Science (1971 -) (2021) Vol. 191, Iss. 4, pp. 1647-1652
Open Access | Times Cited: 21
Potential molecular mechanism underlying cardiac fibrosis in diabetes mellitus: a narrative review
Muhammad Ridwan, Herlina Dimiati, Maimun Syukri, et al.
The Egyptian Heart Journal (2023) Vol. 75, Iss. 1
Open Access | Times Cited: 8
Metabolic Approaches for the Treatment of Dilated Cardiomyopathy
Roberto Spoladore, Giuseppe Pinto, Francesca Daus, et al.
Journal of Cardiovascular Development and Disease (2023) Vol. 10, Iss. 7, pp. 287-287
Open Access | Times Cited: 8
Empagliflozin ameliorates diabetic cardiomyopathy probably via activating AMPK/PGC-1α and inhibiting the RhoA/ROCK pathway
Na Li, Qiuxiao Zhu, Guizhi Li, et al.
World Journal of Diabetes (2023) Vol. 14, Iss. 12, pp. 1862-1876
Open Access | Times Cited: 8
Application of Animal Models in Diabetic Cardiomyopathy
Wang Soo Lee, Jaetaek Kim
Diabetes & Metabolism Journal (2021) Vol. 45, Iss. 2, pp. 129-145
Open Access | Times Cited: 19
The Role of Mitochondrial Biogenesis Dysfunction in Diabetic Cardiomyopathy
Lichan Tao, Tingting Wang, Zheng Lu, et al.
Biomolecules & Therapeutics (2022) Vol. 30, Iss. 5, pp. 399-408
Open Access | Times Cited: 13
Cellular and molecular mechanisms, genetic predisposition and treatment of diabetes-induced cardiomyopathy
Urvashi Sharma, Manodeep Chakraborty, Devid Chutia, et al.
Current Research in Pharmacology and Drug Discovery (2022) Vol. 3, pp. 100126-100126
Open Access | Times Cited: 11
Ironing out the details: ferroptosis and its relevance to diabetic cardiomyopathy
Flobater I. Gawargi, Paras K. Mishra
AJP Regulatory Integrative and Comparative Physiology (2023) Vol. 325, Iss. 6, pp. R665-R681
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top